Masato Iida

Vice President
Patent Attorney
Technical Expert

Practice Areas

Chemistry, Biotechnology, and Pharmaceuticals
IP Legal Services


Ph.D., Graduate School of Agricultural and Life Sciences, The University of Tokyo

Professional Background

MSD K.K. (formerly Banyu Pharmaceutical Co., Ltd.)


Prosecution, trials for invalidation, and suits against trial decisions


Iida, M., Matsuda, M., Komotani H., (2008) Plk3 phosphorylates topoisomerase ll alpha at Thr(1342)–a site not recognized by Plk1, Biochem J., 411(1):27-32

Iida, M., Sasaki, T., Komatani, H., (2009) Overexpression of Plk3 causes morphological change and cell growth suppression in ras pathway-activated cells, J Biochem., 146(4):501-7

Iida, M., (2016) Experimental Medicine: Supplementary Volume, Standards for mouse phenotyping, Patents and laws relating to CRISPR/Cas9, Yodosha Co., Ltd., 97-98

Iida, M., (2018) Experimental Medicine, Breadth of claims related to antibody drugs as considered based on the judgment of Amgen Inc. v. Sanofi S.A., Yodosha Co., Ltd., Vol. 36, No. 9 1490-1491

Iida, M., (2019) Patent Strategies and Technology Development Trends on Pharmaceutical Product Modality, Points to note in the descriptions of “Working Examples and Comparative Examples” in patent specifications
Iida, M., (2019) Managing IP September / October 2019 (Issue 283), Which Experimental Data is Included in Claims of Antibody Drug Patents?, pp.52-54


IAM Patent 1000 2020 (Intellectual Asset Management)
IAM Patent 1000 2019: The World’s Leading Patent Professionals (Intellectual Asset Management)



Dr. Iida is qualified to represent parties in court in IP litigation.  He specializes in biochemistry, molecular biology, and pharmaceuticals.  Dr. Iida has experience constructing target screening systems and evaluation systems for anti-cancer agents (both cell-based and cell-free systems). 

He also has detailed knowledge of genome editing and gave a lecture on notes of caution for patent maps and strategies for patent applications on genome editing at a seminar entitled “The Drug Development which Genome Editing has been Changing” organized by Nikkei Biotechnology & Business in October 2015.  Dr. Iida has been asked to contribute articles to medical magazines based on his wide knowledge and experience in both biotechnology and the IP field.

-Seminar organized by RIPLA (The Rochester Intellectual Property Law Association) in November 2019
Theme: Overview of IP Trends and Practice in Japan and Practical Tips in Light of Legal Comparison between USA and Japan
- Webinar organized by CLA (the California Lawyers Association) in August 2019
Theme: Recent Trends on Patents for Antibody Drugs in Japan

Search Professionals
Practice Area